Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.
about
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesHIV vaccine development: strategies for preclinical and clinical investigationAdditive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesDiverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 bindingA Multi-Vector, Multi-Envelope HIV-1 VaccineInsensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype BHuman immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesNeutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitopeHumoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV InfectionProtection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1.Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes.Characterization of a macaque recombinant monoclonal antibody that binds to a CD4-induced epitope and neutralizes simian immunodeficiency virusInduction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques.Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1.Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities.Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus.Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies.Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells.A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV.The most polymorphic residue on Plasmodium falciparum apical membrane antigen 1 determines binding of an invasion-inhibitory antibody.Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12.Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system.Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes.epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals.Enhanced neutralization of HIV by antibodies displayed on the S-layer of Caulobacter crescentus.Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particlesHIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes.In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.Neutralization interfering antibodies: a "novel" example of humoral immune dysfunction facilitating viral escape?Neutralization of HIV by milk expressed antibody.Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors.Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity.Basic research in HIV vaccinology is hampered by reductionist thinking.Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1).
P2860
Q24561905-406809B2-9A32-4EC9-9D23-AA8F6ACF1E9EQ27025917-DD0425F9-63B8-43DB-9622-2A717BB5A6FBQ27469855-B4A6CB95-E484-4E97-9D3E-F70D447746AFQ27489000-C7174977-9D81-4CCC-845E-2AF6815100EAQ27675486-47D48B48-CB2D-41C0-9ACD-8FC4C8B88384Q28389250-6BB40292-19CC-407D-9866-BE09262813C6Q28469023-8E9A413A-427D-4A47-94E7-03AF89DECF7CQ29619015-B1833C82-03D1-4D3F-9497-501B871CC586Q30431941-8699A2D0-7479-4840-BBA9-00B69F75E01FQ33417195-806B8902-37A7-4E94-8B81-E23B137B8850Q33620546-744B8E04-E4D3-44FB-82D9-700CDC8CE13EQ33647300-AF04FB31-654C-4153-ABD0-425FAA3C5009Q33786382-8A27E63E-2FDE-4A20-BF1A-3FC244825F76Q33787329-BD06697B-2418-45AC-9FAC-DF76E5238E55Q33809225-724AAC14-20C8-4D6A-8402-964E8EBACD13Q33842286-6A4A55B4-6D9E-4381-A7D5-BA16B6369BA3Q33843554-A8AFB2ED-9EA6-403D-859F-4BBFBD4AD7E9Q33870236-B62A20DC-8F89-4FAF-BC49-EEC5B883636DQ33900395-C8E71ED9-FF57-4CC1-A329-E3C1D64F2E34Q33930424-101EA225-AF18-42CB-86C3-2900AB6DAAC6Q34150125-9C841B9D-26D6-4C8D-A36D-8F6A41BA0A75Q34332009-4EE63449-3134-4D9E-BAE3-27138186D248Q34338761-DF2C37A8-2A2F-45C5-8FE2-A5A1192B8469Q34552313-30AED157-FA34-416C-975A-615E5196479CQ34601904-3D2216B0-DFBA-4D2A-A7FD-EEFB5BA5E832Q34781840-AC194F49-A98C-4049-8CEB-B924F88B51F3Q35060140-DB0F0461-DE76-4CD2-AA81-04D6BF8CA38CQ35076711-89C12AFD-7CEC-48C0-AA28-1ACB79F92583Q35192660-B52C287D-D0B2-473E-B606-2A3CE7A5E825Q35598601-C7A844B0-71DB-4509-8ED2-E11A3652E0B5Q35704086-D6D22FBC-546D-48F7-8415-7D5E1AAEA1AFQ35826271-7EAE0596-4062-439A-8DDF-C60C3F1C0892Q35947769-A4B65722-F98F-4144-B56C-036696118D0CQ36404194-243A0CFD-7F57-41C5-B4AE-F40BEE2D02C4Q36492710-4D62D1D9-C01E-4645-8E6A-DFE8E425674FQ36760169-C895C88C-6FA1-4194-B6F2-DED94B14190DQ37388409-1C4FD523-C2A7-481F-85BB-3B36C40B5D21Q37714023-E462D2FF-E253-46B0-B503-12A9AFC62F08Q38025633-FCFADE94-77C1-46C1-A909-BFCF442C31BBQ38206519-E463A86D-CB53-4BC4-BEB7-514D752E83A7
P2860
Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Potent and synergistic neutral ...... lonal antibodies 2F5 and 2G12.
@ast
Potent and synergistic neutral ...... lonal antibodies 2F5 and 2G12.
@en
type
label
Potent and synergistic neutral ...... lonal antibodies 2F5 and 2G12.
@ast
Potent and synergistic neutral ...... lonal antibodies 2F5 and 2G12.
@en
prefLabel
Potent and synergistic neutral ...... lonal antibodies 2F5 and 2G12.
@ast
Potent and synergistic neutral ...... lonal antibodies 2F5 and 2G12.
@en
P2093
P2860
P1433
P1476
Potent and synergistic neutral ...... clonal antibodies 2F5 and 2G12
@en
P2093
Lambert JS
Mascola JR
VanCott TC
P2860
P304
P407
P577
1997-10-01T00:00:00Z